Xenon Pharmaceuticals 2023 Corporate Overview

Xenon Pharmaceuticals is a neurology-focused biopharma company developing small molecule ion channel therapeutics. The company's lead program XEN1101, a potassium channel modulator, demonstrated statistically significant seizure reduction in Phase 2b trials and has advanced to Phase 3 development for focal onset seizures and primary generalized tonic clonic seizures, with additional Phase 2 trials underway in major depressive disorder.